Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 19, 2009

View Archived Issues

Novel B-Raf kinase inhibitors under development at Boehringer Ingelheim for the treatment of cancer

Novel VEGFR-3 (FLT4) inhibitors prepared and tested at sanofi-aventis

Sanofi pasteur to assess dengue vaccine in a pediatric clinical study in Thailand

Phase IIb trial results show longer survival for NSCLC patients treated with TG-4010

Alkermes initiates phase IIa ALKS-27 study for the treatment of COPD

GPC Biotech and Agennix plan merger

Pharmos agrees to sell PRS-639058 and other CB2 agonists to Reperio

Novel inhibitor of soluble epoxide hydrolase prevents cardiac hypertrophy in rats

Phase II clinical trial commences for Merck & Co./Arena niacin receptor agonist

NS-398 inhibits oncogene-regulated hematopoietic differentiation

Bayer discloses novel GSK-3beta inhibitors for hematological disorders

Phase III SOFIA study does not achieve primary endpoint in autistic disorder

Amiloride may prevent cystic fibrosis lung disease

Protia discloses novel deuterated montelukast analogues with antiasthmatic properties

Pfizer describes activity of PF-03716556, a novel acid pump antagonist for GERD

Acyl-AMS inhibitors disrupt Mycobacterium tuberculosis growth in culture

New ocular hypotensive agents for glaucoma imparted in recent Pfizer patent

Diamyd receives approval for phase III study of Diamyd in nine European countries

Bradmer presents update on phase III GLASS-ART clinical trial of Neuradiab in glioblastoma

FDA accepts Amgen's submission and files denosumab BLA for PMO and bone loss

FDA sets PDUFA date for review of Zogenix's NDA for migraine drug Sumavel DosePro

Merck Sharp & Dohme withdraws MAA to EMEA for vorinostat MSD in CTCL

Plethora Solutions and Sciele Pharma provide clinical update on PSD-502 for premature ejaculation

FDA reiterates position of complete response regarding Gilead's aztreonam NDA

FDA extends Hemispherx's NDA review date for Ampligen in CFS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...